| First Author | Ricci B | Year | 2020 |
| Journal | Elife | Volume | 9 |
| PubMed ID | 32755539 | Mgi Jnum | J:298903 |
| Mgi Id | MGI:6477049 | Doi | 10.7554/eLife.54659 |
| Citation | Ricci B, et al. (2020) Osterix-Cre marks distinct subsets of CD45- and CD45+ stromal populations in extra-skeletal tumors with pro-tumorigenic characteristics. Elife 9:e54659 |
| abstractText | Cancer-associated fibroblasts (CAFs) are a heterogeneous population of mesenchymal cells supporting tumor progression, whose origin remains to be fully elucidated. Osterix (Osx) is a marker of osteogenic differentiation, expressed in skeletal progenitor stem cells and bone-forming osteoblasts. We report Osx expression in CAFs and by using Osx-cre;TdTomato reporter mice we confirm the presence and pro-tumorigenic function of TdT(OSX)+ cells in extra-skeletal tumors. Surprisingly, only a minority of TdT(OSX)+ cells expresses fibroblast and osteogenic markers. The majority of TdT(OSX)+ cells express the hematopoietic marker CD45, have a genetic and phenotypic profile resembling that of tumor infiltrating myeloid and lymphoid populations, but with higher expression of lymphocytic immune suppressive genes. We find Osx transcript and Osx protein expression early during hematopoiesis, in subsets of hematopoietic stem cells and multipotent progenitor populations. Our results indicate that Osx marks distinct tumor promoting CD45- and CD45+ populations and challenge the dogma that Osx is expressed exclusively in cells of mesenchymal origin. |
